In fact, promising results from a recent RAS inhibitor trial with tipifarnib sheds light for effective precision drugging of HRAS-mutated HNSCC patients (NCT03719690) and have resulted in fast-track drug review by the FDA (detailed discussion below). Here, HRAS is linked to head and neck squamous cell carcinoma.